On Tuesday, November 19 our CEO Todd Davis and CFO Tavo Espinoza will present a company overview at the Stifel Institutional 2024 Healthcare Conference in New York. Todd and Tavo will review Ligand’s business strategy, recent investment activity, and pipeline partner wins. View the press release here: https://bit.ly/4hKFmjB
Ligand Pharmaceuticals
生物技术研究
Jupiter，Florida 6,370 位关注者
Ligand is a high-growth company with economic rights to some of the world's most important medicines.
关于我们
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Visit our technical products: omniab.com, captisol.com, vernalis.com and ltptechnology.com.
- 网站
-
https://www.ligand.com
Ligand Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Jupiter，Florida
- 类型
- 上市公司
- 创立
- 1987
地点
Ligand Pharmaceuticals员工
动态
-
Today, we recognize the incredible courage and dedication of our veterans, who have safeguarded our freedoms. Your contributions remind us every day of the true meaning of sacrifice and honor. Thank you for your unwavering service. #VeteransDay
-
-
On today’s earnings call, our CEO Todd Davis, and members of the Ligand leadership team highlighted the company’s strong business momentum and portfolio royalty revenue growth as key drivers for raising guidance for the second time this year. View our earnings release here: https://bit.ly/3Azua8B
-
-
We will be hosting our annual Investor Day in Boston on December 10. Our senior management team, led by CEO Todd Davis, will review Ligand's progress and financial performance over the past 12 months and outline our growth strategy and financial outlook for 2025 and beyond. A live webcast and replay will be available. To learn more and register: https://lnkd.in/eUXpxUcA
-
-
Huge congratulations to Merck on the CDC’s Advisory Committee on Immunization Practices (ACIP) recommendation of CAPVAXIVE? for adults 50 and older. This 21-valent pneumococcal conjugate vaccine represents a significant advancement in protecting vulnerable populations against pneumococcal disease. We are thrilled to have CAPVAXIVE as part of our growing #royalty portfolio at Ligand. Read more:??
Today, the CDC’s Advisory Committee on Immunization Practices (#ACIP) voted to update the adult pneumococcal vaccination recommendations, expanding access to those at risk of #pneumococcal disease. Learn more: https://merck.us/3YpTDcK
-
Ligand will report Q3 2024 financial results before the opening of the U.S. financial markets on November 7 followed by a conference call at 8:30am ET. Register: https://bit.ly/40ghrlH
-
-
We are excited to share that Swissmedic has approved FILSPARI? for the treatment of adults with primary IgA nephropathy. This approval will provide more patients suffering from this rare kidney disease with access to this groundbreaking treatment, which is a key part of our commercial royalty portfolio at Ligand. Congratulations to our long-standing partner, Travere Therapeutics, and CSL, on this achievement. Read more ?
Today we announced with CSL Vifor that Swissmedic has approved FILSPARI? (sparsentan) for the treatment of #IgAnephropathy (#IgAN). #InRareForLife Press release: bit.ly/402PX2V
-
-
Congratulations to Palvella Therapeutics and Matt Korenberg on today’s announcement. We are pleased that Matt has joined our long-standing partner Palvella and look forward to success and collaboration in the years ahead. Read more ?
Today, we are excited to welcome Matthew Korenberg as our new Chief Financial Officer! Matt is a seasoned #biotech executive with significant operational and financial leadership experience. His contributions will be instrumental as we work to become the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Learn more: https://bit.ly/3YdjUe7
-
-
We are pleased to see Gilead Sciences' remdesivir, which is formulated with Ligand's Captisol, has been donated for emergency use to support Rwanda’s response to the Marburg Virus Disease (MVD) outbreak. Read more here: https://ow.ly/hZBW50TKRhx
-
We are excited to see Palvella Therapeutics continued progress to advance QTORIN?, a potential treatment for microcystic lymphatic malformations, a rare and chronically debilitating genetic disease. ? The #FDA Office of Orphan Products Development awards grants annually to support the development of safe and effective medical products to address unmet medical needs for patients with rare diseases or conditions. Palvella’s Phase 3 QTORIN? clinical trial was 1 of 7 new clinical trials that was awarded a grant in 2024. ? Read more ?
Today, we announced Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million which will support the advancement of our ongoing Phase 3 single-arm baseline-controlled trial in microcystic lymphatic malformations. This underscores our belief in the potential of QTORIN? rapamycin which has also received FDA Breakthrough Therapy, Fast Track, and Orphan Designations for this serious, rare and chronically debilitating genetic disease. Learn more: https://bit.ly/3BrEnnz #lymphaticmalformations #raredisease?
-